<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01210352</url>
  </required_header>
  <id_info>
    <org_study_id>EN3319-302</org_study_id>
    <nct_id>NCT01210352</nct_id>
  </id_info>
  <brief_title>Effectiveness, Safety, and Tolerability Study of Oxymorphone Immediate Release (IR) Oral Liquid in Post Surgical Pediatric Subjects</brief_title>
  <official_title>An Open-Label, Non-randomized, Multicenter, Ascending Dose by Age, Single- and Multiple-Dose Evaluation of the Effectiveness, Safety, and Tolerability of Oral Liquid Oxymorphone HCl Immediate-Release Oral Liquid for Acute Postoperative Pain in Pediatric Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Endo Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Endo Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effectiveness, tolerability, and safety of
      oxymorphone immediate release (IR) oral liquid as an analgesic for acute postoperative pain
      in pediatric subjects.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Anticipated">February 2018</completion_date>
  <primary_completion_date type="Anticipated">February 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of safety and tolerability will be based on the incidence of Adverse Events(AEs), AEs resulting in discontinuation and serious adverse events</measure>
    <time_frame>Safety = Up to 48 hours</time_frame>
    <description>Single Dose (pain assessment) Effectiveness = baseline, .25. .5. 1. 1.5. 2, 4, 6, 8, 12, 24 post dose; Multi-Dose (pain assessment) Effectiveness= baseline, .5, 1, 1.5, and 2 hrs post dose 1; and immediately prior to all remaining doses administered up through 48 hrs.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine and report the the pharmacokinetic profile of oxymorphone IR oral liquid in pediatric subjects in order to determine appropriate dosing recommendations.</measure>
    <time_frame>Up to 48 Hours</time_frame>
    <description>Single-Dose PK: baseline, .25, .5, 1, 1.5, 2, 4, 6, 8, 12, &amp; 24 hrs; Multi-Dose PK = baseline, .5, 1, 1.5, and 2 hrs post dose 1; immediately prior to doses 2, 3, 4, 5, 6, 7; and at .5, 1, 1.5 and 2 hrs post Dose 7.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Post Operative Pain</condition>
  <arm_group>
    <arm_group_label>CII Drug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open Label</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxymorphone HCl</intervention_name>
    <description>Comparison of different dosages of drug, 0.05mg/kg, 0.10mg/kg, 0.15mg/kg or 0.20mg/kg oral liquid oxymorphone</description>
    <arm_group_label>CII Drug</arm_group_label>
    <other_name>Opana</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males or females between 2 to ≤12 years of age. Females of child-bearing potential
             must be practicing abstinence or using a medically acceptable form of contraception
             (eg, intrauterine device, hormonal birth control, or double barrier method). For the
             purpose of this study, all peri- and post-pubertal females will be considered to be of
             child-bearing potential unless they are biologically sterile or surgically sterile for
             more than 1 year

          2. Subjects must be at least 10 kg and BMI ≤30

          3. Scheduled to have a surgery for which oral opioid analgesia will be needed to manage
             postoperative pain for at least 24 hours (Single-Dose Phase) or 48 hours
             (Multiple-Dose Phase)following intraoperative and/or postoperative parenteral
             analgesia

          4. Be hospital inpatients, expected to be hospitalized for at least 24 hours (Single-Dose
             Phase) and 48 hours (Multiple-Dose Phase) following the initial administration of
             oxymorphone immediate release

          5. Available lab results, either intraoperatively (prior to surgical incision) or from
             within 21 days preoperatively, for clinical chemistry and hematology laboratory
             analytes (the results must have been reviewed by the Investigator for study
             eligibility)

          6. Able to provide pain assessment evaluations using an age-appropriate instrument
             provided in the protocol

          7. On an intravenous analgesic regimen utilizing a short-acting opioid analgesic
             following surgery AND anticipated to be switched to an oral opioid as part of the
             analgesic regimen (according to institution SOC)

          8. Demonstrated the ability to tolerate clear fluids following surgery according to the
             SOC at each institution

          9. Informed of the nature of the study and written informed consent has been obtained
             from the legally responsible parent(s)/legal guardian(s)

         10. Provided assent in accordance with IRB requirements

         11. Line in place for blood sampling

        Exclusion Criteria:

          1. Known allergies or sensitivities to oxymorphone or other opioid analgesics

          2. Known sensitivity to any component of the study drug

          3. Life expectancy &lt;4 weeks

          4. Positive pregnancy test at screening (females of reproductive age only)

          5. Pregnant and/or lactating

          6. Cyanotic heart disease

          7. Respiratory, hepatic, renal, neurological, psychological disease, or any other
             clinically significant condition that would, in the Investigator's opinion, preclude
             participation in the study

          8. Preoperative opioids administered for a period of more than 72 hours in duration

          9. Abdominal trauma that would interfere with absorption of study drug

         10. Increased intracranial pressure

         11. Respiratory condition requiring intubation

         12. History of uncontrolled seizures that are not being managed with anticonvulsants

         13. Significant prior history of substance abuse or alcohol abuse

         14. Received any investigational drug within 30 days prior to the first dose of study
             drug, or are scheduled to receive an investigational drug other than oxymorphone HCl
             immediate-release oral liquid during the course of the study

         15. Received a monoamine oxidase inhibitor (MAOI) within 14 days prior to the start of
             study drug

         16. Received oxycodone or oxymorphone within 48 hours prior to study start

         17. Investigator anticipates that the subject and/or parent(s)/legal guardian(s) would be
             unable to comply with the protocol

         18. Subject (and/or parent[s]/legal guardian[s]) is(are) unable to communicate effectively
             with study personnel at an age-appropriate level
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Todd Kirby, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Endo Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Arizona Medical Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arkansas Children's Hospital</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana Univeristy School of Medicine</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma Health Sciences Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monroe Carell Jr. Children's Hospital at Vanderbilt</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Medical Center Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 17, 2010</study_first_submitted>
  <study_first_submitted_qc>September 27, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 28, 2010</study_first_posted>
  <last_update_submitted>January 15, 2018</last_update_submitted>
  <last_update_submitted_qc>January 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>surgical pain</keyword>
  <keyword>acute pain</keyword>
  <keyword>Acute Post Surgical Pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxymorphone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

